BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), is being studied in Parkinson's disease, Long COVID, and Alzheimer's disease, while BIV201 (continuous-infusion terlipressin) targets refractory ascites.
Analyst coverage of this micro-cap stock is limited. Two analysts tracked by S&P Global have published 12-month price targets of $5.00 and $5.51, producing a mean of approximately $5.26, which we round to a clean central target of $5.25. The rating carries a "Strong Buy" designation. The narrow dollar range ($5.00 to $5.51) reflects consensus on the scale of potential upside rather than strong disagreement, but the small sample size means the figure should be treated with caution rather than as a broad Wall Street consensus. Other aggregators report fewer or no current targets, underscoring how lightly followed the name is. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The latest verified market price is about $1.13, within a 52-week range of $0.82 to $3.79. Reaching $5.25 would require a gain of roughly 365%, which is a very large move for any equity and especially demanding for a pre-revenue biotechnology company. The path would almost certainly depend on positive clinical data or a strategic partnership, because the company does not currently generate product revenue and is valued at a market capitalization of only about $12 million.
The most important drivers are clinical catalysts. Bezisterim is an oral candidate designed to cross the blood-brain barrier and reduce neuroinflammation and insulin resistance. Positive topline results from the SUNRISE-PD trial in early Parkinson's disease or the ADDRESS-LC trial in Long COVID could materially change the risk-reward profile. In liver disease, BIV201 holds FDA (U.S. Food and Drug Administration) Orphan Drug and Fast Track designations, with a planned Phase 3 trial in cirrhosis and ascites. A partnership, licensing deal, or non-dilutive funding would also strengthen the balance sheet and sentiment.
The principal obstacles are financial and scientific. BioVie has a short estimated cash runway, and its history includes a 1-for-10 reverse stock split in July 2025 aimed at maintaining Nasdaq's minimum bid-price requirement. Persistent cash burn creates ongoing dilution risk, and a failed or inconclusive clinical trial could sharply compress the share price. As a micro-cap with thin liquidity, the stock is also vulnerable to outsized volatility on modest news flow.
The $1.00 level is psychologically significant given the company's listing-compliance history, while the 52-week low of $0.82 is the nearest notable support level. On the upside, the 52-week high of $3.79 represents a meaningful prior ceiling that would need to be cleared well before any move toward $5.25. The stock trades near the lower portion of its annual range, reflecting the current uncertainty around its pipeline.
Analyst price targets typically reflect a roughly 12-month research horizon, though no explicit horizon was disclosed with these targets. Investors should watch topline data from the SUNRISE-PD and ADDRESS-LC trials, updates on BIV201's Phase 3 program, financing announcements and cash-burn commentary in quarterly reports, and any Nasdaq listing-compliance developments. These events, rather than broad market trends, are likely to determine the trajectory toward or away from the $5.25 level. From what I see, monitoring these milestones is essential for any position in this name.
In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to stay on top of names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For a volatile, thinly traded name like BIVI, systematic signal monitoring can add useful context alongside fundamental research.
The $5.25 central target is an analyst-derived average built from only two published targets, and it sits roughly 365% above the current price, making the required move very large. The upside rests almost entirely on clinical success for bezisterim or BIV201, or on a transformational partnership. Against that stand a short cash runway, ongoing dilution risk, and binary trial outcomes that could as easily compress the share price as lift it. With such thin coverage and no revenue base, the $5.25 figure is best understood as a scenario-based estimate rather than a probable outcome, and investors should monitor the clinical and financing calendar closely. I’m watching this closely as new data emerges.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIVI advanced for three days, in 194 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIVI's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIVI as a result. In 83 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BIVI turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
BIVI moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for BIVI moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BIVI broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.105) is normal, around the industry mean (3.498). P/E Ratio (-0.436) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. BIVI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology